2025
Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian follow-upSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experience
2024
Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024, 25: e96-e102. PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3Lymphoma
2023
Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience
Hamouche R, Foss F, Mirza S, Di M, Isufi I, Bar N, Gowda L, Perreault S, Roberts K, Seropian S, Sethi T. Predictors of Outcome for Allogeneic Stem Cell Transplantation with a Reduced Intensity Pentostatin/TBI Conditioning Regimen in T-Cell Lymphomas: A Single Center Experience. Blood 2023, 142: 2172. DOI: 10.1182/blood-2023-189414.Peer-Reviewed Original ResearchT-cell lymphomaTotal body irradiationAggressive T-cell lymphomaReduced intensity conditioning regimenHematopoietic stem cell transplantationRefractory T-cell lymphomaNodal T-cell lymphomasIntensity conditioning regimenPotential curative optionStem cell transplantationConditioning regimenAdult patientsCurative optionRetrospective reviewBody irradiationCell transplantationSingle agentPatientsRegimenPentostatinAlloSCTTransplantationLymphoma
2021
EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas
Sethi T, Gerstein R, Schiffer M, Amin K, Agarwal S, Foss F. EPOCH Is a Safe and Effective Treatment Option for Aggressive T-Cell Lymphomas. Blood 2021, 138: 4547. DOI: 10.1182/blood-2021-151238.Peer-Reviewed Original ResearchAggressive T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaAnaplastic large cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaAngioimmunoblastic T-cell lymphomaAdult T-cell leukemia/lymphomaProgression-free survivalOverall response rateNon-Hodgkin lymphomaResponse rateR settingOverall survivalCR rateAdverse effectsPanniculitis-like T-cell lymphomaGrade 3 adverse effectsGrade 4 adverse effectsMedian progression-free survivalAllogeneic stem cell transplantPeripheral T-cell lymphomaT-cell leukemia/lymphomaYale-New Haven HospitalFirst lineEfficacy of etoposide
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply